Specify a stock or a cryptocurrency in the search bar to get a summary
Alpine Immune Sciences Inc
ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Address: 188 East Blaine Street, Seattle, WA, United States, 98102
Analytics
WallStreet Target Price
24 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALPN
Dividend Analytics ALPN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALPN
Stock Valuation ALPN
Financials ALPN
Results | 2019 | Dynamics |